BMS345541 hydrochloride (Synonyms: IKK Inhibitor III) |
| Catalog No.GC12399 |
A selective inhibitor of IKKα and IKKβ
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 547757-23-3
Sample solution is provided at 25 µL, 10mM.
BMS-345541 is a highly selective inhibitor of IKK-1 and IKK-2 with IC50 values of 4μM and 0.3μM, respectively [1].
BMS-345541 is a highly selective inhibitor of IKK that inhibits NF-κB-dependent transcription of pro-inflammatory cytokines both in vitro and in vivo. This specificity is proved in the assay measuring the IKK-2-catalyzed phosphorylation of GST-IκB. In this assay, BMS-345541 fails to inhibit other serine/threonine and tyrosine kinases. This selectivity is also evident in cells, only the stimulus-induced phosphorylation of IκB was inhibited by BMS-345541 whereas other signal transduction cascades were unaffected [1].
Since the IKK/ NFκB pathway is important for viability of leukemic cells and is a predictor of relapse in T-ALL, BMS-345541 is tested in some T-ALL cell lines. It is found that BMS-345541 can induce apoptosis and an accumulation of cells in the G2/M phase of the cell cycle. BMS-345541 can be used in combination with traditional therapies to overcome resistance to chemotherapeutic agents [2].
References:
[1] James R. Burke, Mark A. Pattoli, Kurt R. Gregor, Patrick J. Brassil, John F. MacMaster, Kim W. McIntyre, Xiaoxia Yang, Violetta S. Iotzova, Wendy Clarke, Joann Strnad, Yuping Qiu and F. Christopher Zusi. BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice. J. Biol. Chem. 2003, 278:1450-1456.
[2] Francesca Buontempo, Francesca Chiarini, Daniela Bressanin, Giovanna tabellini, Fraia Melchionda, Andrea pession, Milena Fini, Luca M. Neri, James A. McCubrey and Alberto M. Martelli. Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia. Cell Cycle. 2012, 11 (13): 2467-2475.
| Kinase experiment [1]: | |
|
Enzyme Assays |
Assays measuring the enzyme-catalyzed phosphorylation of GST-IκBα were performed by adding enzyme (IKK-2, IKK-1 or IKK-ε, typically to a final concentration of 0.5 μg/mL) at 30℃ to solutions of 100 μg/mL GST- IκBα and 5 μM [33P]ATP in 40 mM Tris HCl, pH 7.5, containing 4 mM MgCl2, 34 mM sodium phosphate, 3 mM NaCl, 0.6 mM potassium phosphate, 1 mM KCl, 1 mM dithiothreitol, 3% (w/v) glycerol, and 250 μg/mL bovine serum albumin. The specific activity of [33P]ATP used in the assay was 100 Ci/mmol. After 5 mins, the kinase reactions were stopped by the addition of 2× Laemmli sample buffer and heat-treated at 90℃ for 1 min. The samples were then loaded on to NuPAGE 10% BisTris gels. After completion of SDS-PAGE, gels were dried on a slab gel dryer. The bands were then detected using a 445Si PhosphorImager, and the radioactivity was quantified using ImageQuant software. Under these conditions, the degree of phosphorylation of GST-IκBα was linear with time and concentration of enzyme. |
| Cell experiment [1]: | |
|
Cell lines |
THP-1 monocytic cells |
|
Preparation method |
Soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reaction Conditions |
1 ~ 100 μM or 0.04 ~ 25 μM; 60 mins |
|
Applications |
BMS-345541 inhibited the TNFα-stimulated phosphorylation of Iκ-Bα in a dose-dependent manner (IC50 = 4 μM), and reduced the stimulated production of TNFα, IL-1β, IL-8 and IL-6 (IC50 = 1 ~ 5 μM). |
| Animal experiment [1]: | |
|
Animal models |
Female BALB/c mice |
|
Dosage form |
2 mg/kg (1 mL/kg), i.v.; 10 mg/kg (5 mL/kg), p.o. |
|
Applications |
Oral administration of BMS-345541 to mice resulted in prolonged serum drug levels, with concentrations sustained at or above 1 μM for many hrs. BMS-345541 exhibited 100% oral bioavailability. At the dose of 10 mg/kg, BMS-345541 inhibited the production of TNFα induced by LPS and exhibited 50% inhibition. At the dose of 100 mg/kg, BMS-345541 completely inhibited TNFα production. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Burke JR, Pattoli MA, Gregor KR, et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem, 2003, 278(3): 1450-1456. |
|
| Cas No. | 547757-23-3 | SDF | |
| Sinónimos | IKK Inhibitor III | ||
| Chemical Name | N'-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine;hydrochloride | ||
| Canonical SMILES | CC1=CC2=C(C=C1)N=C(C3=NC=C(N23)C)NCCN.Cl | ||
| Formula | C14H18ClN5 | M.Wt | 291.78 |
| Solubility | ≥ 60 mg/mL in Water | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4272 mL | 17.1362 mL | 34.2724 mL |
| 5 mM | 0.6854 mL | 3.4272 mL | 6.8545 mL |
| 10 mM | 0.3427 mL | 1.7136 mL | 3.4272 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *